Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4546 AL 4560

Promise of new Alzheimer's drug is dashed after lack of evidence

Hawkes N.

BMJ. 2016 Nov 24;355:i6362. doi: 10.1136/bmj.i6362.

Pioglitazone for the treatment of Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Investig Drugs. 2017 Jan;26(1):97-101. doi: 10.1080/13543784.2017.1265504. Epub 2016 Dec 4.

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, Farid RM, Blanco-Prieto MJ, Billa N, Hanafy AS.

J Control Release. 2017 Jan 10;245:95-107. doi: 10.1016/j.jconrel.2016.11.025. Epub 2016 Nov 23.

Sixty seconds on . . . solanezumab

Hawkes N.

BMJ. 2016 Nov 29;355:i6389. doi: 10.1136/bmj.i6389.

Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials

Canevelli M, Quarata F, Remiddi F, Lucchini F, Lacorte E, Vanacore N, Bruno G, Cesari M.

Pharmacol Res. 2017 Jan;115:218-223. doi: 10.1016/j.phrs.2016.11.035. Epub 2016 Nov 30.

3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish"

Choi SH, Kim YH, Quinti L, Tanzi RE, Kim DY.

Mol Neurodegener. 2016 Dec 9;11(1):75. doi: 10.1186/s13024-016-0139-7.

A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease

Barron M, Gartlon J, Dawson LA, Atkinson PJ, Pardon MC.

Exp Gerontol. 2017 Aug;94:103-107. doi: 10.1016/j.exger.2016.12.006. Epub 2016 Dec 12.

PHARMAID study protocol: Randomized controlled trial to assess the impact of integrated pharmaceutical care at a psychosocial intervention on caregiver's burden in Alzheimer's disease or related diseases

Novais T, Moutet C, Delphin-Combe F, Dauphinot V, Colin C, Krolak-Salmon P, Mouchoux C; PHARMAID study group.

Contemp Clin Trials. 2017 Feb;53:137-142. doi: 10.1016/j.cct.2016.12.020. Epub 2016 Dec 19.

Development and Structural Modification of BACE1 Inhibitors

Gu T, Wu WY, Dong ZX, Yu SP, Sun Y, Zhong Y, Lu YT, Li NG.

Molecules. 2016 Dec 22;22(1):4. doi: 10.3390/molecules22010004.

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Penninkilampi R, Brothers HM, Eslick GD.

J Neuroimmune Pharmacol. 2017 Mar;12(1):194-203. doi: 10.1007/s11481-016-9722-5. Epub 2016 Dec 26.

Solanezumab and the amyloid hypothesis for Alzheimer's disease

Le Couteur DG, Hunter S, Brayne C.

BMJ. 2016 Dec 29;355:i6771. doi: 10.1136/bmj.i6771.

Tacrine: In vivo veritas

Jarrott B.

Pharmacol Res. 2017 Feb;116:29-31. doi: 10.1016/j.phrs.2016.12.033. Epub 2016 Dec 28.

Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions

Dey A, Bhattacharya R, Mukherjee A, Pandey DK.

Biotechnol Adv. 2017 Mar-Apr;35(2):178-216. doi: 10.1016/j.biotechadv.2016.12.005. Epub 2016 Dec 30.

Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins

Veugelen S, Dewilde M, De Strooper B, Chávez-Gutiérrez L.

Methods Enzymol. 2017;584:59-97. doi: 10.1016/bs.mie.2016.10.029. Epub 2016 Dec 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias